Monday, November 09, 2020

Well, Mondays are always slow, but I still have hope that more non-election, non-covid articles will make it through my search filters.



Due in January.

https://blogs.lse.ac.uk/usappblog/2020/11/08/book-review-the-internet-in-everything-freedom-and-security-in-a-world-with-no-off-switch-by-laura-denardis/

Book Review: The Internet in Everything: Freedom and Security in a World with No Off Switch by Laura DeNardis

In The Internet in Everything: Freedom and Security in a World with No Off Switch, Laura DeNardis offers an exploration of the invisible, complex and concerning worldwide network of technologies often referred to as the Internet of Things, focusing particularly on the pressing issues of governance and jurisdiction.

One of the most pressing concerns in contemporary cybersecurity scholarship is how the ‘Internet of Things’ is affecting, and will affect, both individual security and privacy and the security of the state. As more and more devices connect to the internet and become integrated into every aspect of daily life, there is an ongoing battle between device efficacy and device security, between device utility and individual privacy, between security threat and threat mitigation.





No good deed goes unpunished.

https://www.cnbc.com/2020/11/09/zoom-and-other-stay-at-home-stocks-are-getting-crushed-on-the-positive-vaccine-news.html

Zoom and other ‘stay-at-home’ stocks are getting crushed on the positive vaccine news

Shares of Zoom Video fell sharply on Monday morning as names benefitting from people staying at home due to the coronavirus pandemic lost their appeal following the release of positive coronavirus vaccine data.

Zoom Video traded more than 15% lower in the premarket. Fellow “stay-at-home” stocks Amazon and Netflix dropped 3.4% and 5.4%, respectively. Teladoc Health slid 6.4% and Shopify declined by 5.1%.

Those losses came after Pfizer and BioNTech reported that their coronavirus vaccine candidate showed a 90% efficacy rate in preventing infections during a late-stage trial.



No comments: